C. Frank Bennett

46.7k total citations · 23 hit papers
227 papers, 30.1k citations indexed

About

C. Frank Bennett is a scholar working on Molecular Biology, Genetics and Cellular and Molecular Neuroscience. According to data from OpenAlex, C. Frank Bennett has authored 227 papers receiving a total of 30.1k indexed citations (citations by other indexed papers that have themselves been cited), including 183 papers in Molecular Biology, 55 papers in Genetics and 36 papers in Cellular and Molecular Neuroscience. Recurrent topics in C. Frank Bennett's work include Neurogenetic and Muscular Disorders Research (53 papers), RNA Interference and Gene Delivery (52 papers) and RNA Research and Splicing (48 papers). C. Frank Bennett is often cited by papers focused on Neurogenetic and Muscular Disorders Research (53 papers), RNA Interference and Gene Delivery (52 papers) and RNA Research and Splicing (48 papers). C. Frank Bennett collaborates with scholars based in United States, Canada and United Kingdom. C. Frank Bennett's co-authors include Eric E. Swayze, Frank Rigo, Stanley T. Crooke, Adrian R. Krainer, Susan M. Freier, Yimin Hua, Brenda F. Baker, Gene Hung, Daniel A. Norris and Don W. Cleveland and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

C. Frank Bennett

224 papers receiving 29.5k citations

Hit Papers

The Nuclear-Retained Nonc... 1992 2026 2003 2014 2010 2006 2010 2011 2004 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Nuclear-Retained Noncoding RNA MALAT1 Regulates Alternative Splicing by Modulating SR Splicing Factor Phosphorylation
    2010 1.7k citations Susan M. Freier, C. Frank Bennett et al. profile →
  2. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
    2006 1.7k citations Mark J. Graham, Bridget Lollo et al. profile →
  3. RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
    2010 1.1k citations C. Frank Bennett et al. profile →
  4. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43
    2011 959 citations C. Frank Bennett, Don W. Cleveland et al. profile →
  5. MicroRNA-143 Regulates Adipocyte Differentiation
    2004 831 citations Eigen Peralta, Eric G. Marcusson et al. profile →
  6. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
    2016 736 citations Richard S. Finkel, Claudia A. Chiriboga et al. profile →
  7. RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention
    2013 670 citations Frank Rigo, C. Frank Bennett et al. Neuron profile →
  8. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
    2015 647 citations Richard S. Geary, C. Frank Bennett et al. profile →
  9. RNA-Targeted Therapeutics
    2018 612 citations Stanley T. Crooke, C. Frank Bennett et al. profile →
  10. Regulating Gene Expression through RNA Nuclear Retention
    2005 569 citations Susan M. Freier, C. Frank Bennett et al. profile →
  11. Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis
    2012 563 citations Gene Hung, C. Frank Bennett et al. Neuron profile →
  12. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model
    2011 556 citations Frank Rigo, Gene Hung et al. profile →
  13. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function
    1999 526 citations C. Frank Bennett et al. profile →
  14. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.
    1992 525 citations C. Frank Bennett et al. profile →
  15. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
    2010 501 citations Gene Hung, Frank Rigo et al. profile →
  16. Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion
    2013 493 citations Frank Rigo, C. Frank Bennett et al. profile →
  17. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
    2013 492 citations Timothy M. Miller, C. Frank Bennett et al. profile →
  18. Results from a phase 1 study of nusinersen (ISIS-SMN Rx ) in children with spinal muscular atrophy
    2016 460 citations Claudia A. Chiriboga, Basil T. Darras et al. profile →
  19. Therapeutic Antisense Oligonucleotides Are Coming of Age
    2019 416 citations C. Frank Bennett profile →
  20. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA
    2014 378 citations C. Frank Bennett, Frank Rigo et al. profile →
  21. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy
    2017 362 citations Sarah L. DeVos, C. Frank Bennett et al. profile →
  22. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration
    2019 339 citations C. Frank Bennett, Frank Rigo et al. profile →
  23. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases
    2019 242 citations C. Frank Bennett, Adrian R. Krainer et al. Annual Review of Neuroscience profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
C. Frank Bennett 23.5k 6.4k 6.1k 3.6k 3.5k 227 30.1k
Heidi Phillips 11.1k 0.5× 3.7k 0.6× 3.4k 0.6× 2.4k 0.7× 8.0k 2.3× 140 23.3k
Bengt Westermark 16.4k 0.7× 3.5k 0.5× 4.2k 0.7× 1.5k 0.4× 1.9k 0.5× 340 29.1k
Charles G. Eberhart 13.6k 0.6× 6.9k 1.1× 4.1k 0.7× 2.5k 0.7× 846 0.2× 426 23.2k
Francisco E. Baralle 12.0k 0.5× 4.7k 0.7× 1.7k 0.3× 7.5k 2.1× 1.1k 0.3× 249 20.7k
Fumiaki Tanaka 9.2k 0.4× 1.7k 0.3× 3.1k 0.5× 3.4k 0.9× 3.4k 1.0× 360 15.8k
Mariano Barbacid 31.1k 1.3× 1.7k 0.3× 5.9k 1.0× 2.0k 0.6× 12.4k 3.5× 266 52.4k
Hideyuki Saya 14.2k 0.6× 1.6k 0.2× 4.4k 0.7× 1.5k 0.4× 825 0.2× 458 23.7k
Joachim Herz 15.9k 0.7× 1.4k 0.2× 5.4k 0.9× 1.9k 0.5× 5.2k 1.5× 284 35.7k
Charles D. Stiles 11.0k 0.5× 2.2k 0.3× 3.1k 0.5× 950 0.3× 1.9k 0.5× 139 18.0k
Gideon Rechavi 18.6k 0.8× 1.7k 0.3× 6.0k 1.0× 724 0.2× 929 0.3× 405 27.0k

Countries citing papers authored by C. Frank Bennett

Since Specialization
Citations

This map shows the geographic impact of C. Frank Bennett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Frank Bennett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Frank Bennett more than expected).

Fields of papers citing papers by C. Frank Bennett

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Frank Bennett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Frank Bennett. The network helps show where C. Frank Bennett may publish in the future.

Co-authorship network of co-authors of C. Frank Bennett

This figure shows the co-authorship network connecting the top 25 collaborators of C. Frank Bennett. A scholar is included among the top collaborators of C. Frank Bennett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Frank Bennett. C. Frank Bennett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gu, Chen, Wenxin Song, Kai Chen, et al.. (2024). Tool to Resolve Distortions in Elemental and Isotopic Imaging. Journal of the American Chemical Society. 146(29). 20221–20229.
2.
Bennett, C. Frank, et al.. (2023). Antisense drugs for rare and ultra-rare genetic neurological diseases. Neuron. 111(16). 2465–2468. 9 indexed citations
3.
Ling, Karen, et al.. (2023). Long-Term SMN- and Ncald-ASO Combinatorial Therapy in SMA Mice and NCALD-ASO Treatment in hiPSC-Derived Motor Neurons Show Protective Effects. International Journal of Molecular Sciences. 24(4). 4198–4198. 7 indexed citations
4.
Kit, Wai, Juergen Scharner, Ana S.H. Costa, et al.. (2021). ASO-Based PKM Splice-Switching Therapy Inhibits Hepatocellular Carcinoma Growth. Cancer Research. 82(5). 900–915. 79 indexed citations
5.
Bennett, C. Frank, Adrian R. Krainer, & Don W. Cleveland. (2019). Antisense Oligonucleotide Therapies for Neurodegenerative Diseases. Annual Review of Neuroscience. 42(1). 385–406. 242 indexed citations breakdown →
6.
Jangi, Mohini, Christina Fleet, Patrick Cullen, et al.. (2017). SMN deficiency in severe models of spinal muscular atrophy causes widespread intron retention and DNA damage. Proceedings of the National Academy of Sciences. 114(12). E2347–E2356. 91 indexed citations
7.
Kirschner, Janbernd, Eugenio Mercuri, Richard S. Finkel, et al.. (2017). Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): results of the phase 3 CHERISH study. Neuropediatrics. 48.
8.
Soriano, Armand, Lawrence Bai, Todd Machemer, et al.. (2017). The Distinct and Cooperative Roles of Toll-Like Receptor 9 and Receptor for Advanced Glycation End Products in Modulating In Vivo Inflammatory Responses to Select CpG and Non-CpG Oligonucleotides. Nucleic Acid Therapeutics. 27(5). 272–284. 21 indexed citations
9.
Snider, Lauren, Zizhen Yao, Rabi Tawil, et al.. (2015). DICER/AGO-dependent epigenetic silencing of D4Z4 repeats enhanced by exogenous siRNA suggests mechanisms and therapies for FSHD. Human Molecular Genetics. 24(17). 4817–4828. 40 indexed citations
10.
DeVos, Sarah L., Guojun Chen, Kaoru Yamada, et al.. (2013). Antisense Reduction of Tau in Adult Mice Protects against Seizures. Journal of Neuroscience. 33(31). 12887–12897. 250 indexed citations
11.
Elyakim, Eran, Einat Sitbon, Alexander Faerman, et al.. (2010). hsa-miR-191 Is a Candidate Oncogene Target for Hepatocellular Carcinoma Therapy. Cancer Research. 70(20). 8077–8087. 126 indexed citations
12.
Goldfarb, Roy D., C. Frank Bennett, Madeline Butler, Thomas P. Condon, & Joseph E. Parrillo. (2010). Targeting Host E-Selectin Expression by Antisense Oligodeoxynucleotides as Potential Antiendotoxin Therapy In Vivo. Oligonucleotides. 20(5). 253–261. 2 indexed citations
13.
14.
Drygin, Denis, Seongjoon Koo, Ranjan J. Perera, Stephen Barone, & C. Frank Bennett. (2005). Induction of Toll-like Receptors and NALP/PAN/PYPAF Family Members by Modified Oligonucleotides in Lung Epithelial Carcinoma Cells. Oligonucleotides. 15(2). 105–118. 6 indexed citations
15.
Bennett, C. Frank. (2002). Efficiency of Antisense Oligonucleotide Drug Discovery. Antisense and Nucleic Acid Drug Development. 12(3). 215–224. 17 indexed citations
16.
Condon, Thomas P., et al.. (2001). ADAM17 but Not ADAM10 Mediates Tumor Necrosis Factor-α and L-Selectin Shedding from Leukocyte Membranes. Antisense and Nucleic Acid Drug Development. 11(2). 107–116. 56 indexed citations
17.
Templin, Michael V., Arthur A. Levin, Mark J. Graham, et al.. (2000). Pharmacokinetic and Toxicity Profile of a Phosphorothioate Oligonucleotide Following Inhalation Delivery to Lung in Mice. Antisense and Nucleic Acid Drug Development. 10(5). 359–368. 46 indexed citations
18.
Katz, Steven M., et al.. (1997). Effect of ICAM-1/1FA-1 blockade on pancreatic islet allograft survival, function, and early cytokine production. Transplantation Proceedings. 29(1-2). 748–749. 7 indexed citations
19.
Boggs, Russell T., et al.. (1997). Characterization and Modulation of Immune Stimulation by Modified Oligonucleotides. Antisense and Nucleic Acid Drug Development. 7(5). 461–471. 50 indexed citations
20.
Bennett, C. Frank, et al.. (1987). Phosphorylation of PI-specific phospholipase C by protein kinase C in vivo. Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Heidi Phillips Breakdown of academic impact, for papers by Bengt Westermark Breakdown of academic impact, for papers by Charles G. Eberhart Breakdown of academic impact, for papers by Francisco E. Baralle Breakdown of academic impact, for papers by Fumiaki Tanaka Breakdown of academic impact, for papers by Mariano Barbacid Breakdown of academic impact, for papers by Hideyuki Saya Breakdown of academic impact, for papers by Joachim Herz Breakdown of academic impact, for papers by Charles D. Stiles Breakdown of academic impact, for papers by Gideon Rechavi
Rankless by CCL
2026